生活習慣病ナーシング　11　糖尿病とメタボリックシンドローム4

出版社： メヂカルフレンド社
著者：
発行日： 2008-11-14
分野： 看護学  >  臨床/成人/老人
ISBN： 9784839214517
電子書籍版： 2008-11-14 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,970 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,970 円(税込)

購入する

商品紹介

わが国の医療対策の最重要課題である生活習慣病をもつ患者の看護に役立つことを念頭に置いたシリーズ企画。安全・安楽な看護、根拠をもった看護の実践ができるように情報を整理。予防に対する知識から最新の治療・看護に関する知見まで、臨床の今を反映した内容。施設内医療から在宅医療の支援まで、セルフケアに必要な知識・技術に関する情報を整理。

目次

  • 生活習慣病ナーシング　11　糖尿病とメタボリックシンドローム4

    ―目次―

    第１章　動脈硬化と臓器障害
    第２章　虚血性心疾患
    第３章　脳血管障害
    第４章　大動脈瘤
    第５章　閉塞性動脈硬化症
    第６章　動脈硬化症の大規模臨床研究
    第７章　糖尿病とメタボリックシンドロームの先進医療

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1 動脈硬化と臓器障害

P.13 掲載の参考文献
1) メタボリックシンドローム診断基準検討委員会: メタボリックシンドロームの定義と診断基準, 日本内科学会雑誌, 94(4): 188-203, 2005.
 
2) 伊藤裕: メタボリックドミノとは; 生活習慣病の新しいとらえ方, 日本臨牀, 61: 1837-1843, 2003.
Medical*Online
3) 清原裕: 久山町研究が示すメタボリックシンドロームと虚血性心疾患の関連, 日本臨牀, 64（suppl 9): 64-67, 2006.
 
4) Nakamura, T., et al.: Magnitude of Sustained Multiple Risk Factors for Ischemic Heart Disease in Japanese Employees: A Case-Control Study, Jpn.Circ.J., 65: 11-17, 2001.
PubMed
5) Tagher, G., et al.: Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus, J.Clin.Endocrinol. Metab., 82: 3619-3624, 1997.
 
6) Howard, G., et al.: Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities（ARIC) Study, JAMA, 279: 119-124, 1998.
PubMed

2 虚血性心疾患

P.70 掲載の参考文献
1) Pyorala, K., et al.: Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study, Diabetes Care, 27: 1735-1740, 2004.
PubMed
2) 柳下芳寛監, 国立国際医療センター看護部 ICU: 疾患別・処置別でわかる ICU 看護, 日総研出版, 2003.
 
3) 日和田邦夫監, 檜垣實男, 山西文子編: エクセルナース 1: 循環器編, 改訂版, メディカルレビュー社, 2005.
 
4) 平山篤志監: Q & A からはじめよう！ 冠動脈疾患マスターブック, ハートナーシング, 2006年秋季増刊, メディカ出版, 2006.
 
5) 樫田光夫監: STEP UP でどんどんわかる急性冠症候群ケアマニュアル, ハートナーシング, 2005年秋季増刊, メディカ出版, 2005.
 
6) 樫田光夫: 心臓カテーテルマスターへの第一歩！ 冠動脈インターベンション（PCI) のケア "1day" レクチャー, ハートナーシング, 20(8), 2007.
 
7) 国立循環器病センター看護部編: CCU 看護マニュアル, ハートナーシング, 1993年冬季増刊, メディカ出版, 1993.
 
8) 国立循環器病センター看護部編: ICU 看護マニュアル 疾患看護・外科的処置編, ハートナーシング, 1997年秋季増刊, メディカ出版, 1997.
 

4 大動脈瘤

P.144 掲載の参考文献
1) Haimovici, H.: Haimovici's Vascular Surgery Principle and Techniques, fourth edition, Blackwell Science, 1996, p.759-827.
 
2) Egen, T.J., et al.: Computed tomography in the diagnosis of aortic aneurysm, dissection or traumatic injury, Radiology, 5: 18-31, 1980.
 
3) 由谷親夫, 松尾汎編: 大動脈瘤・大動脈解離の臨床と病理, 医学書院, 2004, p.2-8.
 
4) 田邉晃久編: 循環器疾患治療スタンダード2004-2005, 今月の治療臨時増刊号, 11: 282-285, 2003.
 
5) 隈崎達夫, 中村仁信編: 第 3 回国際 MDCT シンポジウム講演録, Excerpta Medica.
 
6) 国立循環器病センター心臓血管部門編: 新心臓血管外科管理ハンドブック, 南江堂, 2005.
 
7) 藤田敏郎: 高血圧; 分子メカニズムから病態・診断・治療まで, 羊土社, 1995.
 

5 閉塞性動脈硬化症

P.173 掲載の参考文献
1) Trans-Atrantic Inter-Society Consensus（TASC) Working Group: Management of peripheral arterial disease, J. Vasc. Surg., 31: 1-296, 2000.
 

6 動脈硬化症の大規模臨床研究

P.202 掲載の参考文献
1) Kannel, W.B., et al.: Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study, Ann. Intern. Med., 90: 85-91, 1979.
PubMed
2) 垂井清一郎: 厚生省特定疾患原発性高脂血症調査研究班 昭和61年度研究報告書, 1987.
 
3) Okamura, T., et al.: The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort, Atherosclerosis, 190: 216-223, 2007.
 
4) Verschuren, W.M., et al.: Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study, Jama, 274: 131-136, 1995.
PubMed
5) The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease, Jama, 251: 351-364, 1984.
PubMed
6) The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering, Jama, 251: 365-374, 1984.
PubMed
7) WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up, Report of the Committee of Principal Investigators, Lancet, 2: 379-385, 1980.
 
8) Frick, M.H., et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease, N.Engl.J.Med., 317: 1237-1245, 1987.
PubMed
9) Shepherd, J., et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group, N.Engl.J.Med., 333: 1301-1307, 1995.
 
10) Downs, J.R., et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. AirForce/Texas Coronary Atherosclerosis Prevention Study, Jama, 279: 1615-1622, 1998.
 
11) Sever, P.S., et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm（ASCOT-LLA): a multicentre randomised controlled trial, Lancet, 361: 1149-1158, 2003.
 
12) Colhoun, H.M., et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study（CARDS): multicentre randomised placebo-controlled trial, Lancet, 364: 685-696, 2004.
PubMed
13) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial（ALLHAT-LLT), Jama, 288: 2998-3007, 2002.
PubMed
14) Shepherd, J., et al.: Pravastatin in elderly individuals at risk of vascular disease（PROSPER): a randomised controlled trial, Lancet, 360: 1623-1630, 2002.
 
15) Keech, A., et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus（the FIELD study): randomised controlled trial, Lancet, 366: 1849-1861, 2005.
 
16) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study（4S), Lancet, 344: 1383-1389, 1994.
PubMed
17) Sacks, F.M., et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N.Engl.J.Med., 335: 1001-1009, 1996.
 
18) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease（LIPID) Study Group, N.Engl.J.Med., 339: 1349-1357, 1998.
 
19) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360: 7-22, 2002.
PubMed
20) LaRosa, J.C., et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N.Engl.J.Med., 352: 1425-1435, 2005.
PubMed
21) Pedersen, T.R., et al.: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial, Jama, 294: 2437-2445, 2005.
PubMed
22) Clofibrate and niacin in coronary heart disease, Jama, 231: 360-381, 1975.
PubMed
23) Rubins, H.B., et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N.Engl.J.Med., 341: 410-418, 1999.
 
24) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention（BIP) study, Circulation, 102 : 21-27, 2000.
PubMed
25) Schwartz, G.G., et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes : the MIRACL study : a randomized controlled trial, Jama, 285 : 1711-1718, 2001.
PubMed
26) de Lemos, J.A., et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial, Jama, 292: 1307-1316, 2004.
 
27) Cannon, C.P., et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N.Engl.J.Med., 350: 1495-1504, 2004.
PubMed
28) Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study, J.Atheroscler.Thromb., 7: 110-121, 2000.
PubMed
29) Matsuzaki, M., et al.: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia, Circ.J., 66: 1087-1095, 2002.
PubMed
30) Nakamura, H., et al.: Primary prevention of cardiovascular disease with pravastatin in Japan（MEGA Study): a prospective randomised controlled trial, Lancet, 368: 1155-1163, 2006.
PubMed
31) Yokoyama, M., et al.: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients（JELIS): a randomised open-label, blinded endpoint analysis, Lancet, 369: 1090-1098, 2007.
PubMed
32) Honey, K.: Drug designed to raise HDL levels falls down, J.Clin.Invest., 117: 282, 2007.
 
33) 塚本和久: 動脈硬化症予防のための新しい治療薬, 治療, 89（7): 2333-2338, 2007.
Medical*Online
34) 日本高血圧学会高血圧治療ガイドライン作成委員会: 高血圧治療ガイドライン2004年版, ライフサイエンス出版, 2004, p.47-53.
 
35) Hansson, L., et al.: Effects of intensive blood-pressure lowering and acetylsalicylic acid in patients with hypertension: principal results of the Hypertension Optimal Treatment（HOT) randomized trial, Lancet, 351: 1755-1762, 1998.
PubMed
36) UK Prospective Diabetes Study（UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complicatons in patients with type 2 diabetes（UKPDS 33), Lancet, 352: 837-853, 1998.
 
37) Curb, J.D., et al. for the Systolic Hypertension in the Elderly Program Cooperative Research Group: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension, JAMA, 276: 1886-1892, 1996.
 
38) Tuomilehto, J., et al.: Effects of calcium-channel blocker in older patients with diabetes and systolic hypertension, N.Engl.J.Med. 340: 677-684, 1999.
PubMed
39) Heart Outcomes Prevention Evaluation（HOPE) Study Investigators: Effects oframipril on cardiovascular and microvascular outcpmes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy, Lancet, 355: 253-259, 2000.
 
40) Lindholm, L., et al. for the LIFE study group: Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study（LIFE): a randomised trial against atenolol, Lancet, 359: 1004-1010, 2002.
 
41) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial（ALLHAT), JAMA, 288: 2981-2997, 2002.
PubMed
42) Julius, S., et al. for the VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risl treated with regimens based on valsartan or amlodipine: he VALUE randomised trial, Lancet, 363: 2022-2031, 2004.
 
43) Dahlof, B., et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm（ASCOT-BPLA): a multicenter randomised controlled trial, Lancet, 366: 895-906, 2005.
PubMed
44) Lewis, E.J., et al.: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborate Study Group, N.Engl.J.Med., 329: 1456-1462, 1993.
 
45) Katayama, S., et al.: Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: A randomized controlled study（JAPAN-IDDM), Dib.Res.Clin.Pract., 55: 113-121, 2002.
 
46) Brenner, B.M., et al. for the RENAAL Study Group: Effects of losartan on renaland cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N.Engl.J.Med., 345: 861-869, 2001.
 
47) Lewis, E.J., et al. for the Collaborative Study Group: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N.Engl.J.Med., 345: 851-860, 2001.
 
48) Parving, H., et al. for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the progression of diabetic nephropathy in patients with type 2 diabetes, N.Engl.J.Med., 345: 870-878, 2001.
 
49) Viberti, G., Wheelton, N.M., Micro Albuminuria Reduction with VALsartan（MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect, Circulation, 106: 672-678, 2002.
 
50) Makino, H., et al. for the INNOVATION Study Group: Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes, Diabetes Care, 30: 1577-1578, 2007.
 
51) The Shiga Microalbuminuria Reduction Trial（SMART) Group: Reduction of microalbuminuria in patients with type 2 diabetes. The Shiga Microalbuminuria Reduction Trial（SMART), Diabetes Care, 30: 1581-1583, 2007.
 
52) Barnett, A.H., et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy, N.Engl.J.Med., 351: 1952-1961, 2004.
PubMed
53) Lewis, J.B., et al.: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group, Am.J.Kidney Dis., 34: 809-817, 1999.
 
54) Yamada, T., et al.: Development, progression, and regression of microalbuminuria in Japanese patients with type 2 diabetes under tight glycemic and blood pressure control. The Kashiwa Study, Diabetes Care, 28: 2733-2738, 2005.
PubMed

7 糖尿病とメタボリックシンドロームの先進医療

P.231 掲載の参考文献
1) 日本透析医学会統計調査委員会: 図説わが国の慢性透析療法の現況; 2006年12月 31日現在, 日本透析医学会, 2007, p.12.
 
2) 2004 Annual Reports-International Pancreas Transplant Registry at the University of Minnesota, www.iptr.umn.edu/
 
3) 矢崎義雄監, 寺岡慧, 他: 分子糖尿病学の進歩, 金原出版, 1999, p.133-142.
 
4) 金澤康徳: 膵臓移植の現況, 糖尿病, 43: 267-271, 2000.
 
5) 赤沼安夫, 野田光彦編, 寺岡慧, 他: 糖尿病, 日本評論社, 2004, p.256-266.
 
6) Shapiro, A.M., et al.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen, N.Engl.J.Med., 343: 230-238, 2000.
PubMed
7) Shapiro, A.M., et al.: Edmonton's islet success has indeed been replicated elsewhere, Lancet, 362: 1242, 2003.
PubMed
8) Nagata, H., et al.: In situ cooling of pancreata from non-heart-beating donors prior toprocurement for islet transplantation, Transplant. Proc., 37: 3393-3395, 2005.
PubMed
9) Noguchi, H., et al.: Modified two-layer preservation method（M-Kyoto/PFC) improves islet yields in islet isolation, Am.J.Transplant., 6: 496-504, 2006.
 
10) Ricordi, C., et al.: Automated method for isolation of human pancreatic islets, Diabetes, 37: 413-420, 1988.
PubMed
11) 山田祐一郎, 他: 心停止ドナーからの膵島移植によってインスリン離脱した1型糖尿病の1症例, 糖尿病, 47: 945-950, 2004.
 
12) Ryan, E.A., et al.: Five-yeay follow-up after clinical islet transplantation, Diabetes, 54: 2060-2069, 2005.
 
13) Sassa, M., et al.: A single transplantation of the islets can produce glycemic stability and reduction of basal insulin requirement, Diabetes Res.Clin.Pract., 73: 235-240, 2006.
PubMed
14) Takahashi, K., et al.: Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131: 861-872, 2007.
PubMed
15) Yamada, Y., et al., SUIT（secretory unit of islets in transplantation): An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes, Diabetes Res.Clin.Pract., 74: 222-226, 2006.
 
16) Nakanishi, M., et al.: Pancreatic Tissue Formation from Murine Embryonic StemCells in vitro, Differentiation, 75: 1-11, 2007.
 
17) D'Amour, K.A., et al.: Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells, Nat.Biotechnol., 24: 1392-1401, 2006.
PubMed
18) Takahashi, K., et al.: Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131: 861-872, 2007.
PubMed
19) Suzuki, A., et al.: Prospective isolation of multipotent pancreatic progenitors using flow-cytometric cell sorting, Diabetes, 53: 2143-2152, 2004.
PubMed
20) 濱本耕平, 小島至: 糖尿病の再生医療, 最新医学, 62（4): 117, 2007.
 
21) 門脇孝, 他編: 糖尿病学, 西村書店, 2007, p.1045.
 

書評

最近チェックした商品履歴

Loading...